Organon & Co. (NYSE:OGN) Hits New 12-Month Low – Here’s What Happened

Shares of Organon & Co. (NYSE:OGN) hit a new 52-week low during trading on Monday . The stock traded as low as $5.76 and last traded at $5.7650, with a volume of 620674 shares trading hands. The stock had previously closed at $5.84.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on OGN. Barclays upped their price target on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. Zacks Research downgraded shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Finally, Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, Organon & Co. presently has an average rating of “Reduce” and an average target price of $8.50.

Organon & Co. Price Performance

The stock has a fifty day moving average of $7.47 and a two-hundred day moving average of $8.01. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 8.02, a PEG ratio of 0.54 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the firm posted $0.90 EPS. Organon & Co.’s revenue for the quarter was down 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were issued a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a yield of 1.4%. Organon & Co.’s dividend payout ratio is currently 11.27%.

Hedge Funds Weigh In On Organon & Co.

Institutional investors have recently modified their holdings of the stock. Foster Dykema Cabot & Partners LLC bought a new stake in shares of Organon & Co. during the third quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its position in Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares during the last quarter. Rothschild Investment LLC lifted its holdings in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after buying an additional 1,646 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. during the 4th quarter worth $44,000. Finally, Kestra Advisory Services LLC bought a new position in Organon & Co. in the 4th quarter valued at $47,000. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.